They also showed that inhibiting GLUT5 reduces tumor growth and metastasis in vivo, supporting the idea that GLUT5 is not only involved in early-stage prostate carcinogenesis but also plays a critical role in the progression and aggressiveness of the disease. The gene discussed is SLC2A5; the disease is urogenital neoplasm.